Kiniksa Pharmaceuticals International, plc
KNSA
$20.21
-$0.325-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -406.68% | -35.51% | -104.42% | -95.59% | -92.32% |
| Total Depreciation and Amortization | -27.60% | -23.64% | -11.08% | -5.59% | -2.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,047.21% | -10.65% | 118.50% | 100.65% | 97.16% |
| Change in Net Operating Assets | 1,737.70% | 101.67% | 143.91% | 412.58% | 105.98% |
| Cash from Operations | 93.14% | 532.46% | -28.26% | -43.85% | 129.05% |
| Capital Expenditure | -113.08% | -233.33% | -225.00% | -47.29% | -23.81% |
| Sale of Property, Plant, and Equipment | -- | 150.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 228.87% | 25.99% | -86.12% | 246.65% | -264.92% |
| Cash from Investing | 227.46% | 25.83% | -86.28% | 245.59% | -265.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 366.09% | 283.91% | 162.83% | 144.80% | 8.31% |
| Repurchase of Common Stock | -125.93% | -128.38% | -166.87% | -188.16% | -144.84% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 720.47% | 443.67% | 160.26% | 129.87% | -40.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 612.34% | 64.70% | -172.81% | 249.60% | -6,124.90% |